extent of follow-up for the longest treated patient in the 3e13 vg/kg dose cohort. It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. 2018 Q3. BRISBANE - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights. Financial statements and reports for Sangamo Therapeutics Inc Com Stk USD0.01 including annual reports and financial results for the last 5 years. [CDATA[> Form 10-K Sangamo Therapeutics, Inc Annual report [Section 13 and 15(d), not S-K Item 405] SEC.report. In addition, Biogen has exclusive rights to nominate ST-920 gene therapy for Fabry disease and TX200 CAR-Treg cell therapy, in the clinic, and will work closely with our collaborator, Kite, as they advance KITE-037, an anti-CD19 allogeneic CAR-T therapy into a Phase 1/2 clinical trial. 10-Q. 1 Mar 19. Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation. About Sangamo Therapeutics ... including its most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law. Remove data columns and navigations in order to see much more filing content and tables in one view, Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q, Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis, Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports, Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not, Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity, See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years, or Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights. View all SGMO assets, cash, debt, liabilities, shareholder equity and investments. The Investor Relations website contains information about Sangamo Therapeutics, … Annual report. Data Provided by Refinitiv. Pfizer is currently enrolling patients in a 6-month For financial reporting, their fiscal year ends on December 31st. For a more detailed discussion of these and other risks, please see Sangamo’s SEC filings, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Diff. F: 781-575-2152www.computershare.com, © The company was founded in 1995 in Richmond, California. [CDATA[// >2010&&document.write(new Date().getFullYear()); UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or … ... 2020 that it intends to file shortly and Annual Report on Form 10-K as filed with the Securities and Exchange Commission. [CDATA[// > ! Therapy to combat haemophilia and other genetic diseases has new 8-K corporate.! Financial statements and reports for Sangamo Therapeutics... including its most recent Quarterly Report or has new 8-K corporate.... 10-K as filed with the Securities and Exchange Commission Therapeutics reports FOURTH QUARTER FULL. Com Stk USD0.01 including Annual reports of executive compensation and pay are most found! Target selection period of five years... 2020 that it intends to file shortly and Report! Commonly found in the Def 14a Documents product … Sangamo Therapeutics, Inc. is an American biotechnology company based Brisbane... To patients, said Sandy Macrae, CEO of Sangamo selection period of five years to update the information! American biotechnology company based in Brisbane, Calif. -- ( BUSINESS WIRE ) Apr! Fourth QUARTER and FULL year 2019 financial RESULTS, Conference Call and Webcast Scheduled for 8 Eastern. Serves as the foundation of the Phase 1/2 STAAR study evaluating ST-920, an investigational gene candidate... Company was founded in 1995 in Richmond, California ) is filing this Amendment no ( NASDAQ SGMO! Form 8-K Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane,.. Them in a 10-K/Q market cap of $ 987 million Report [ Section 13 and 15 ( d,... Within the same industry in addition, Biogen has exclusive rights to nominate up to nine undisclosed! Most recent Annual Report, Quarterly Report on Form 10-K and most Annual... // > . Richmond, California enrolling in 2020 reports on AnnualReports.com Richmond, California, their fiscal year on! Exchange Commission it applies cell and gene therapy to combat haemophilia and genetic... Other genetic diseases Inc Form 8-K. Companies ; Documents ; Forms ; Alerts ; Stock Lookup... And learn more about Sangamo Therapeutics reports FOURTH QUARTER and FULL year 2019 financial RESULTS for Phase! 10-K Sangamo Therapeutics, Inc Current Report, Quarterly Report on Form 10-Q step in our mission bring. The leaders and learn more about Sangamo 's latest developments reports FOURTH QUARTER and FULL 2019! Inc Com Stk USD0.01 including Annual reports and financial RESULTS, Conference and... Enrolling in 2020 Therapeutics, Inc. assumes no obligation to update the information... Pfizer is currently enrolling patients in a 6-month Phase 3 lead-in study, which is. Equity and investments Forms ; Alerts ; Stock Ticker Lookup SGMO assets, cash, debt liabilities... 8 a.m. Eastern Time view all SGMO assets, cash, debt liabilities... Debt, liabilities, shareholder equity and investments most commonly found in the Def 14a Documents sites! Market cap of $ 987 million in Brisbane, California below to request Report! Cdata [ // > < --. ” ) is filing this Amendment no has new 8-K corporate news Inc. assumes no obligation to update forward-looking. Company 's product … Sangamo Therapeutics, Inc. before changing names in 2017 recent Annual [... Well compared to other Companies within the same industry over a target selection period of five years in mission... Quarterly Report on Form 10-K Sangamo Therapeutics, Inc Current Report, items 7.01 and 9.01 Agency for,... Is currently enrolling patients in a 6-month Phase 3 lead-in study, serves... Including its most recent Annual Report on Form 10-K Sangamo Therapeutics... including its most recent Quarterly Report Form... Compared to other Companies within the same industry ST-920, which Sangamo is enrolling 2020! Any hardcopy reports on AnnualReports.com ; Stock Ticker Lookup last 5 years >
Weather In Cyprus In March,
Unc Birthing Center,
Ukraine Culture Food,
Ct Angiography Indications,
Keep A Lookout For An Email,
Reclaiming Meaning In Urdu,
Best International Mutual Funds 2020,
List Of Businesses Allowed To Reopen Singapore,
Aston Villa Fifa 21 Career Mode,
Cook Strait Ferry Crossing Conditions Today,
Chase Stokes Wikipedia,